1. Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and in the United States: A Center for International Blood and Marrow Transplant Research Report 
Pooja Khandelwal, Heather R. Millard, Elizabeth Thiel, Hisham Abdel-Azim, Allistair A. Abraham, Jeffery J. Auletta, Farid Boulad, Valerie I. Brown, Bruce M. Camitta, Ka Wah Chan, Sonali Chaudhury, Morton J. Cowan, Miguel Angel-Diaz, Shahinaz M. Gadalla, Robert Peter Gale, Gregory Hale, Kimberly A. Kasow, Amy K. Keating, Carrie L. Kitko, Margaret L. MacMillan, Richard F. Olsson, Kristin M. Page, Adriana Seber, Angela R. Smith, Anne B. Warwick, Baldeep Wirk, Parinda A. Mehta 
Biology of Blood and Marrow Transplantation 
Volume 23, Issue 8, Pages (August 2017)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
(A) Conditioning intensity for all allo-transplants between 2008 and The percentage of allo-transplant patients who received either myeloablative, reduced-intensity, or nonmyeloablative conditioning regimen is shown. (B) Donor relation in allo-HSCT between 2008 and The percentage of all allo-transplants that received either an HLA-identical sibling donors, other relative donors, or unrelated donors are shown. (C) Stem cell sources in allo-HSCT between 2008 and The percentage of all allo-transplants that received either a bone marrow, PBSC, or UCB are shown. (D) Allo-transplant for various leukemia subtypes between 2008 and The percentage of all leukemia patients who received an allogeneic transplant for AML, ALL, chronic myeloid leukemia, MDS/MPN, biphenotypic leukemia (BL), or other leukemia (OL) is shown. (E) Disease status before an allo-transplant in ALL is shown. Percentage of ALL patients transplanted in CR1, CR2, CR3, primary induction failure (PIF), first relapse, and second or greater relapse is shown. (F) Disease status before an allo-transplant in AML is shown. Percentage of AML patients transplanted in CR1, CR2, CR3, PIF, first relapse, and second or greater relapse is shown. (G) Percentage of patients with lymphoma who received an allo-transplant between 2008 and (H) Percentage of patients with lymphoma who received an auto-transplant between 2008 and 2014.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(A) Percentage of patients with various solid tumors who underwent an auto-transplant between 2008 and Percentage of all auto-transplant patients with an underlying diagnosis of a neuroblastoma, medulloblastoma, other CNS tumors, Ewing's family tumors, retinoblastoma, germ cell tumors, Wilms tumor, gonadal tumors, rhabdomyosarcoma, and other solid tumors. (B) Percentage of patients with various solid tumors who received tandem auto-HSCTs between 2008 and Percentage of all tandem auto-transplant patients with an underlying diagnosis of medulloblastoma, other CNS tumors, neuroblastoma, Ewing's family tumors, retinoblastoma, germ cell tumors, and gonadal tumors.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions